Meiji Seika Pharma Co., Ltd.

Meiji Seika Pharma Co., Ltd. is a Japanese pharmaceutical company primarily engaged in the research, development, manufacturing, and sale of ethical pharmaceuticals, agricultural chemicals, and veterinary drugs. The company's core business focuses on infectious diseases, vaccines, and central nervous system (CNS) disorders, alongside a significant presence in generic drugs. Headquartered in Chuo-ku, Tokyo, Japan, its mission is to contribute to global health and wellness through innovative pharmaceutical solutions and manufacturing excellence, embodying ideas that promote health worldwide, particularly in infectious disease control.

The company's product portfolio includes a range of antibacterial drugs, such as penicillin-based antibiotics and MEIACT, and vaccines like the self-amplifying mRNA COVID-19 vaccine KOSTAIVE and the five-in-one vaccine QUINTOVAC. Meiji Seika Pharma also develops treatments for CNS disorders, including the antidepressant DEPROMEL and the antianxiety drug MEILAX, and drugs for hematological oncology such as REZUROCK. Beyond its proprietary products, the company provides Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) services through subsidiaries like Medreich Ltd. and Meiji Seika Pharmatech.

Under the leadership of President and Representative Director Toshiaki Nagasato and Chairman Daikichiro Kobayashi, Meiji Seika Pharma is actively expanding its global footprint and product pipeline. Recent developments include the launch of KOSTAIVE in December 2023 and REZUROCK in 2024. The company established a new office in Boston in August 2024 to explore investment opportunities in innovative drugs and technologies. Furthermore, it has formed new subsidiaries, Taiwan Meiji Pharma Co., Ltd. (December 2024) and Meiji Pharma Asia Pte. Ltd. (expected Spring 2026), to bolster its presence and commercial activities in Taiwan and the ASEAN region, respectively. These initiatives align with the "Meiji Group 2026 Vision" to become a leading company in Asia in the field of infectious diseases, with a strong focus on combating antimicrobial resistance (AMR) and ensuring a stable supply of essential pharmaceuticals, including domestic production of antibiotic active pharmaceutical ingredients.